SecBot SecBot
8-K ·Filed Jun 16, 2026

DTIL

PRECISION BIOSCIENCES INC
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001628280-26-043526
8-K material event: Items 1.01
Actionable Insight • Neutral

The maturity extension reduces near-term refinancing risk for Precision BioSciences, but does not provide new capital. Monitor for future financing needs or pipeline catalysts that could affect the company's ability to service debt.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
DTIL ▲ +10.31% at T+60d
NEUTRAL call +10.31% · α vs SPY +7.16% · entry $6.50 → $7.17
Entry = T+0 close
Jun 16, 2026
via day close
T+1d
+4.77%
call +4.77% · α +3.99%
$6.81
settled 4mo ago
T+5d
+3.69%
call +3.69% · α +4.73%
$6.74
settled 4mo ago
T+20d
+28.00%
call +28.00% · α +26.68%
$8.32
settled 3mo ago
T+60d
+10.31%
call +10.31% · α +7.16%
$7.17
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Precision BioSciences amended its existing loan agreement with Banc of California, extending the Term Loan maturity date from June 30, 2027 to December 31, 2029. No new borrowing, changes to principal, interest rate, or other terms were disclosed. The extension provides additional runway for the company's operations and pipeline development.

Key Facts

  • Term Loan maturity extended by 2.5 years, from June 30, 2027 to December 31, 2029
  • No changes to principal amount, interest rate, or other material terms disclosed
  • Amendment executed with Banc of California, the existing lender

Financial Impact

No dollar amounts disclosed; the amendment extends the maturity of an existing term loan without altering principal or interest terms.

debt_maturity

Risk Factors

  • Company still requires additional capital to fund operations beyond the extended maturity date
  • No new cash infusion; existing cash burn rate unchanged

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-043526
Document: a1011stamendmenttoarlsa.htm0001628280-26-043526
Document: 0001628280-26-043526-index-headers.html0001628280-26-043526
Document: 0001628280-26-043526-index.html0001628280-26-043526
Document: 0001628280-26-043526.txt0001628280-26-043526
11 reports for DTIL
Performance horizon
67% Hit rate @ T+1 2 of 3 directional calls Went positive at some point 3 of 3 best @ T+60▲ +14.89%May 27, 2026
Filters
Rows
Reports for DTIL — sortable, filterable
TypeNow
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$7.19 $6.36▼ −11.54%▼ −10.82%$6.53 (−9.18%)
Aug 24, 2026
9w ago
8-K
BULLISH ★ 7/10
$8.45 $8.55▲ +1.18%▲ +0.86%$6.53 (−22.72%)
Aug 6, 2026
11w ago
8-K
BULLISH ★ 7/10
$7.42 $7.49▲ +0.94%▲ +0.33%$6.53 (−11.99%)
Jul 27, 2026
13w ago
8-K
NEUTRAL ★ 3/10
$7.25 $7.17▼ −1.10%▼ −1.34%$6.53 (−9.93%)
Jul 1, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$7.88 $8.18▲ +3.81%▲ +3.94%$6.53 (−17.13%)
Jun 16, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$6.50 $6.81▲ +4.77%▲ +3.99%$6.53 (+0.46%)
May 27, 2026
21w ago
8-K
BULLISH ★ 7/10
$7.59 $6.92▼ −8.83%▼ −9.38%$6.53 (−13.97%)
May 26, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$7.59 $6.92▼ −8.83%▼ −9.38%$6.53 (−13.97%)
May 5, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$7.45 $7.52▲ +0.94%▼ −0.45%$6.53 (−12.35%)
Apr 8, 2026
28w ago
DEFA14A
NEUTRAL ★ 3/10
$5.99 $6.61▲ +10.35%▲ +9.78%$6.53 (+9.02%)
Showing 10 of 11

US Market Status

Market Open — Closes in 4h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026